Treat-to-target in systemic lupus erythematosus: Where are we today?

M. Mosca, D. Boumpas, I. N. Bruce, R. Cervera, L. Czirják, T. Dörner, F. Houssiau, S. Jacobsen, M. Schneider, J. S. Smolen, A. E. Voskuyl, R. F. Van Vollenhoven

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-totarget approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume30
Issue number4 SUPPL.73
Publication statusPublished - 2012

Fingerprint

Systemic Lupus Erythematosus
Rheumatoid Arthritis
Therapeutics
Clinical Trials
Research

Keywords

  • Damage
  • Outcomes
  • Systemic lupus erythematosus
  • Treat-to-target

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Mosca, M., Boumpas, D., Bruce, I. N., Cervera, R., Czirják, L., Dörner, T., ... Van Vollenhoven, R. F. (2012). Treat-to-target in systemic lupus erythematosus: Where are we today? Clinical and Experimental Rheumatology, 30(4 SUPPL.73).

Treat-to-target in systemic lupus erythematosus : Where are we today? / Mosca, M.; Boumpas, D.; Bruce, I. N.; Cervera, R.; Czirják, L.; Dörner, T.; Houssiau, F.; Jacobsen, S.; Schneider, M.; Smolen, J. S.; Voskuyl, A. E.; Van Vollenhoven, R. F.

In: Clinical and Experimental Rheumatology, Vol. 30, No. 4 SUPPL.73, 2012.

Research output: Contribution to journalArticle

Mosca, M, Boumpas, D, Bruce, IN, Cervera, R, Czirják, L, Dörner, T, Houssiau, F, Jacobsen, S, Schneider, M, Smolen, JS, Voskuyl, AE & Van Vollenhoven, RF 2012, 'Treat-to-target in systemic lupus erythematosus: Where are we today?', Clinical and Experimental Rheumatology, vol. 30, no. 4 SUPPL.73.
Mosca M, Boumpas D, Bruce IN, Cervera R, Czirják L, Dörner T et al. Treat-to-target in systemic lupus erythematosus: Where are we today? Clinical and Experimental Rheumatology. 2012;30(4 SUPPL.73).
Mosca, M. ; Boumpas, D. ; Bruce, I. N. ; Cervera, R. ; Czirják, L. ; Dörner, T. ; Houssiau, F. ; Jacobsen, S. ; Schneider, M. ; Smolen, J. S. ; Voskuyl, A. E. ; Van Vollenhoven, R. F. / Treat-to-target in systemic lupus erythematosus : Where are we today?. In: Clinical and Experimental Rheumatology. 2012 ; Vol. 30, No. 4 SUPPL.73.
@article{5da8e69817074183ba55c4c9848bdb1e,
title = "Treat-to-target in systemic lupus erythematosus: Where are we today?",
abstract = "Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-totarget approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.",
keywords = "Damage, Outcomes, Systemic lupus erythematosus, Treat-to-target",
author = "M. Mosca and D. Boumpas and Bruce, {I. N.} and R. Cervera and L. Czirj{\'a}k and T. D{\"o}rner and F. Houssiau and S. Jacobsen and M. Schneider and Smolen, {J. S.} and Voskuyl, {A. E.} and {Van Vollenhoven}, {R. F.}",
year = "2012",
language = "English",
volume = "30",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4 SUPPL.73",

}

TY - JOUR

T1 - Treat-to-target in systemic lupus erythematosus

T2 - Where are we today?

AU - Mosca, M.

AU - Boumpas, D.

AU - Bruce, I. N.

AU - Cervera, R.

AU - Czirják, L.

AU - Dörner, T.

AU - Houssiau, F.

AU - Jacobsen, S.

AU - Schneider, M.

AU - Smolen, J. S.

AU - Voskuyl, A. E.

AU - Van Vollenhoven, R. F.

PY - 2012

Y1 - 2012

N2 - Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-totarget approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

AB - Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-totarget approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

KW - Damage

KW - Outcomes

KW - Systemic lupus erythematosus

KW - Treat-to-target

UR - http://www.scopus.com/inward/record.url?scp=84870276669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870276669&partnerID=8YFLogxK

M3 - Article

C2 - 23072706

AN - SCOPUS:84870276669

VL - 30

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4 SUPPL.73

ER -